52289-56-2

Basic information

• Product Name: Benzene, 1-(bromomethyl)-4-methoxy-2-methyl-
• Synonyms: Benzene,1-(bromomethyl)-4-methoxy-2-methyl;1-(bromomethyl)-4-methoxy-2-methyl-benzene
• CAS NO: 52289-56-2
• Molecular Formula: C9H11BrO
• Molecular Weight: 215.09
• Mol File: 52289-56-2.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(bromomethyl)-4-methoxy-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(bromomethyl)-4-methoxy-2-methyl-(52289-56-2)
• EPA Substance Registry System: Benzene, 1-(bromomethyl)-4-methoxy-2-methyl-(52289-56-2)

Safety Data

• Hazardous Substances Data: 52289-56-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 504, 1984 DOI: 10.1055/s-1984-30883

Upstream product

• 4685-47-6 3,4-dimethylanisole 
• 52289-54-0 4-methoxysalicylaldehyde 
• 6245-57-4 4-methoxy-2-methylbenzoic acid 
• 52289-55-1 (4-methoxy-2-methylphenyl)methanol 

Downstream Products

• 166537-02-6 4-methoxy-2-methylbenzyl (trimethylsilyl)methyl sulfide 
• 91954-12-0 diethyl 4-methoxy-2-methylbenzylphosphonate 

Relevant articles and documents

Design, synthesis, and structure–activity relationship study of potent mapk11 inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target f

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE

The invention relates to activators of soluble guanylate cyclase of formula (I) and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pre